A875

【A875】A875细胞/A875细胞/A875人黑色素瘤细胞Cell line name A-875

Synonyms A875; 875

Accession CVCL_4733

Resource Identification Initiative To cite this cell line use: A-875 (RRID:CVCL_4733)

Comments Doubling time: ~4 days (PubMed=265522).

Omics: Transcriptome analysis by RNAseq.

Caution: Incorrectly indicated in table 2 of PubMed=265522 to originate from a 78 year old male.

Derived from site: Metastatic; Brain, right frontal lobe; UBERON=UBERON_0002810.

Disease Melanoma (NCIt: C3224)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Sex of cell Female

Age at sampling 40Y

Category Cancer cell line

PubMed=4357758; DOI=10.1093/jnci/51.5.1417

Giard D.J., Aaronson S.A., Todaro G.J., Arnstein P., Kersey J.H., Dosik H., Parks W.P.

In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.

J. Natl. Cancer Inst. 51:1417-1423(1973)

 

PubMed=265522; DOI=10.1073/pnas.74.2.565; PMCID=PMC392331

Fabricant R.N., De Larco J.E., Todaro G.J.

Nerve growth factor receptors on human melanoma cells in culture.

Proc. Natl. Acad. Sci. U.S.A. 74:565-569(1977)

 

PubMed=375235; DOI=10.1073/pnas.76.3.1288; PMCID=PMC383236

Sherwin S.A., Sliski A.H., Todaro G.J.

Human melanoma cells have both nerve growth factor and nerve growth factor-specific receptors on their cell surfaces.

Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979)

 

PubMed=6256643; DOI=10.1038/288724a0

Day R.S. 3rd, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.

Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains.

Nature 288:724-727(1980)

 

PubMed=6988327; DOI=10.1007/BF02831503

O'Brien S.J., Shannon J.E., Gail M.H.

A molecular approach to the identification and individualization of human and animal cells in culture: isozyme and allozyme genetic signatures.

In Vitro 16:119-135(1980)

 

PubMed=25502142; DOI=10.1038/ncomms6712; PMCID=PMC4428333

Muller J., Krijgsman O., Tsoi J., Robert L., Hugo W., Song C., Kong X.-J., Possik P.A., Cornelissen-Steijger P.D.M., Geukes Foppen M.H., Kemper K., Goding C.R., McDermott U., Blank C., Haanen J.B.A.G., Graeber T.G., Ribas A., Lo R.S., Peeper D.S.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Nat. Commun. 5:5712.1-5712.15(2014)